114. Egberts F., Pollex A., Egberts J. H., Kaehler K. C., Weichenthal M., Hauschild A. Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH // Onkologie. ‒ 2008. ‒ T. 31, № 7. ‒ C. 380-4.
115. Zhan H., Ma J. Y., Jian Q. C. Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in melanoma patients: A meta-analysis // Clin Chim Acta. ‒ 2018. ‒ T. 484. ‒ C. 136-140.
116. Gao D., Ma X. Serum lactate dehydrogenase is a predictor of poor survival in malignant melanoma // Panminerva Med. ‒ 2017. ‒ T. 59, № 4. ‒ C. 332-337.
117. Cao M. G., Auge J. M., Molina R., Marti R., Carrera C., Castel T., Vilella R., Conill C., Sanchez M., Malvehy J., Puig S. Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma // Anticancer Res. ‒ 2007. ‒ T. 27, № 1B. ‒ C. 595-9.
118. Gassenmaier M., Lenders M. M., Forschner A., Leiter U., Weide B., Garbe C., Eigentler T. K., Wagner N. B. Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors // Target Oncol. ‒ 2021. ‒ T. 16, № 2. ‒ C. 197-205.
119. Henry L., Fabre C., Guiraud I., Bastide S., Fabbro-Peray P., Martinez J., Lavabre-Bertrand T., Meunier L., Stoebner P. E. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein // Int J Cancer. ‒ 2013. ‒ T. 133, № 1. ‒ C. 142-8.
120. Janka E. A., Vanyai B., Szabo I. L., Toka-Farkas T., Varvolgyi T., Kapitany A., Szegedi A., Emri G. Primary tumour category, site of metastasis, and baseline serum S100B and LDH are independent prognostic factors for survival in metastatic melanoma patients treated with anti-PD-1 // Front Oncol. ‒ 2023. ‒ T. 13. ‒ C. 1237643.
121. Partl R., Fastner G., Kaiser J., Kronhuber E., Cetin-Strohmer K., Steffal C., Bohmer-Breitfelder B., Mayer J., Avian A., Berghold A. KPS/LDH index: a simple tool for identifying patients with metastatic melanoma who are unlikely to benefit from palliative whole brain radiotherapy // Support Care Cancer. ‒ 2016. ‒ T. 24, № 2. ‒ C. 523-528.
122. Leiter U., Buettner P. G., Eigentler T. K., Forschner A., Meier F., Garbe C. Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit? // Melanoma Res. ‒ 2010. ‒ T. 20, № 3. ‒ C. 240-6.
123. Mathews J. D., Forsythe A. V., Brady Z., Butler M. W., Goergen S. K., Byrnes G. B., Giles G. G., Wallace A. B., Anderson P. R., Guiver T. A., McGale P., Cain T. M., Dowty J. G., Bickerstaffe A. C., Darby S. C. Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians // BMJ. ‒ 2013. ‒ T. 346. ‒ C. f2360.
124. Rodriguez Rivera A. M., Alabbas H., Ramjaun A., Meguerditchian A. N. Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis // Surg Oncol. ‒ 2014. ‒ T. 23, № 1. ‒ C. 11-6.
125. Podlipnik S., Carrera C., Sanchez M., Arguis P., Olondo M. L., Vilana R., Rull R., Vidal-Sicart S., Vilalta A., Conill C., Malvehy J., Puig S. Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study // J Am Acad Dermatol. ‒ 2016. ‒ T. 75, № 3. ‒ C. 516-24.
126. Romano E., Scordo M., Dusza S. W., Coit D. G., Chapman P. B. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines // J Clin Oncol. ‒ 2010. ‒ T. 28, № 18. ‒ C. 3042-7.
127. Xing Y., Bronstein Y., Ross M. I., Askew R. L., Lee J. E., Gershenwald J. E., Royal R., Cormier J. N. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis // J Natl Cancer Inst. ‒ 2011. ‒ T. 103, № 2. ‒ C. 129-42.
128. Dinnes J., Ferrante di Ruffano L., Takwoingi Y., Cheung S. T., Nathan P., Matin R. N., Chuchu N., Chan S. A., Durack A., Bayliss S. E., et al. Ultrasound, CT, MRI, or PET‐CT for staging and re‐staging of adults with cutaneous melanoma // Cochrane Database of Systematic Reviews. ‒ 2019.10.1002/14651858.CD012806.pub2 № 7.
129. Lazaga F. J., Oz O. K., Adams-Huet B., Anderson J., Mathews D. Comparison of whole-body versus limited whole-body 18F-FDG PET/CT scan in malignant cutaneous melanoma // Clin Nucl Med. ‒ 2013. ‒ T. 38, № 11. ‒ C. 882-4.
130. Ortega-Candil A., Rodriguez-Rey C., Cano-Carrizal R., Cala-Zuluaga E., Gonzalez Larriba J. L., Jimenez-Ballve A., Fuentes-Ferrer M. E., Cabrera-Martin M. N., Perez-Castejon M. J., Garcia Garcia-Esquinas M., Lapena-Gutierrez L., Carreras-Delgado J. L. Breslow thickness and (18)F-FDG PET-CT result in initial staging of cutaneous melanoma: Can a cut-off point be established? // Rev Esp Med Nucl Imagen Mol. ‒ 2016. ‒ T. 35, № 2. ‒ C. 96-101.
131. Sanchez-Sanchez R., Serrano-Falcon C., Rebollo Aguirre A. C. Diagnostic imaging in dermatology: utility of PET-CT in cutaneous melanoma // Actas Dermosifiliogr. ‒ 2015. ‒ T. 106, № 1. ‒ C. 29-34.
132. Jouvet J. C., Thomas L., Thomson V., Yanes M., Journe C., Morelec I., Bracoud L., Durupt F., Giammarile F., Berthezene Y. Whole-body MRI with diffusion-weighted sequences compared with 18 FDG PET-CT, CT and superficial lymph node ultrasonography in the staging of advanced cutaneous melanoma: a prospective study // J Eur Acad Dermatol Venereol. ‒ 2014. ‒ T. 28, № 2. ‒ C. 176-85.
133. Gjorup C. A., Hendel H. W., Pilegaard R. K., Willert C. B., Holmich L. R. Routine X-ray of the chest is not justified in staging of cutaneous melanoma patients // Dan Med J. ‒ 2016. ‒ T. 63, № 12.